Reply to G. Gandaglia et al and K. Lu

J Clin Oncol. 2015 Sep 1;33(25):2833. doi: 10.1200/JCO.2015.62.4643. Epub 2015 Jul 27.

Authors

Justin E Bekelman¹, Nandita Mitra², Elizabeth A Handorf³, Robert G Uzzo³, Stephen M Hahn⁴, Daniel Polsky², Katrina Armstrong⁵

Affiliations

¹ University of Pennsylvania, Philadelphia, PA bekelman@uphs.upenn.edu.
² University of Pennsylvania, Philadelphia, PA.
³ Fox Chase Cancer Center, Philadelphia, PA.
⁴ MD Anderson Cancer Center, Houston, TX.
⁵ Massachusetts General Hospital, Boston, MA.

PMID: 26215947
DOI: 10.1200/JCO.2015.62.4643

No abstract available

Publication types

Letter
Comment

MeSH terms

Androgen Antagonists / therapeutic use*
Antineoplastic Agents, Hormonal / therapeutic use*
Humans
Male
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / radiotherapy*

Substances

Androgen Antagonists
Antineoplastic Agents, Hormonal